The result was corroborated in a second validation cohort of n > 196 mixed stage patients (IST cohort) (Supplementary Fig. 1b), supporting an inverse relationship between CHST11 expression and AR signaling in prostate cancer. Here, CHST11 is linked to prostate carcinoma.